HHS Moves to Boost Production of Vaccine-Manufacturing Supplies

Feb. 18, 2021, 7:46 PM

The federal government is looking to finance the expansion of domestic production in supplies necessary to manufacture Covid-19 vaccines, according to the General Services Administration.

The Biomedical Advanced Research and Development Authority on Wednesday issued three requests for proposals to expand its supply of these pharmaceutical consumables, which are used during vaccine production. Any awarded contracts would be to “expand existing US based manufacturing capacity” for the supplies.

BARDA, part of the Department of Health and Human Services, helps develop countermeasures against emerging diseases. The agency regularly finances new technologies, drugs, and devices that can be used during a public health emergency or biohazard attack.

One contract would expand manufacturing for biocontainers, bottles, fluid transfer sets, and filtration sets with the supplies being delivered by June 2023. Another would do so for single-use bags to hold biopharmaceutical fluids with delivery by the end of 2021, and the third would be for silicone tubing and other related plastic supplies, also to be delivered by the end of the year.

To contact the reporter on this story: Shira Stein in Washington at sstein@bloomberglaw.com

To contact the editors responsible for this story: Fawn Johnson at fjohnson@bloombergindustry.com; Brent Bierman at bbierman@bloomberglaw.com; Karl Hardy at khardy@bloomberglaw.com

To read more articles log in.

Learn more about a Bloomberg Law subscription.